Prosaikogenin F ((2R,3R,4S,5R,6R)-2-{[(1S,2R,4S,5R,8R,9S,10R,13S,14R,17S,18R)-2-hydroxy-9-(hydroxymethyl)-4,5,9,13,20,20-hexamethyl-24-oxahexacyclo[15.5.2.01,1?.0?,1?.0?,1?.0?,13]tetracos-15-en-10-yl]oxy}-6-methyloxane-3,4,5-triol) is a natural product with anticancer and hemolytic properties [1].
Prosaikogenin F ((2R,3R,4S,5R,6R)-2-{[(1S,2R,4S,5R,8R,9S,10R,13S,14R,17S,18R)-2-hydroxy-9-(hydroxymethyl)-4,5,9,13,20,20-hexamethyl-24-oxahexacyclo[15.5.2.01,1?.0?,1?.0?,1?.0?,13]tetracos-15-en-10-yl]oxy}-6-methyloxane-3,4,5-triol) is a natural product with anticancer and hemolytic properties [1].
In vitro
Prosaikogenin F suppressed A549 proliferation with inhibition rates of 40.53%, 92.62% and 93.07% at concentrations of 20, 40 and 60 μg/mL, respectively [1]. The IC50 values of prosaikogenin F on HCT 116 cancer cells was 14.21 μM [2].
In vivo
Intraperitoneal administration of Saikosaponin A and its intestinal metabolite, Prosaikogenin F, showed corticosterone secretion-inducing activity at a dose of 0.1 mmol/kg, and maximally increase it at a dose of 0.4 mmol/kg [3].
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
参考文献
投与量変換
